A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC)

被引：0
|
作者：
Shen, Lin
Yu, Xianjun
Hao, Jihui
Wang, Liwei
Pan, Hongming
Han, Guohong
Xu, Jian-Ming
Zhang, Yanqiao
Yang, Shujun
Chen, Jia
Ying, Jieer
Dai, Guanghai
Li, Mingyu
Begic, Damir
Lu, Brian D.
Xu, Ruihua
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
[3] Tianjin Canc Hosp, Tianjin, Peoples R China
[4] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Shanghai 200030, Peoples R China
[5] Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China
[6] Fourth Mil Med Univ, Dept Liver Dis & Digest Intervent Radiol, Xijing Hosp Digest Dis, Xian 710032, Peoples R China
[7] Acad Mil Med Sci, Hosp 307, Ctr Canc, Beijing, Peoples R China
[8] Harbin Med Univ, Affiliated Hosp 3, Harbin, Peoples R China
[9] Henan Canc Hosp, Zhengzhou, Peoples R China
[10] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
[11] Zhejiang Canc Hosp, Dept Chemotherapy, Hangzhou, Zhejiang, Peoples R China
[12] Peoples Liberat Army, Gen Hosp, Beijing, Peoples R China
[13] Celgene Corp, Summit, NJ USA
[14] Celgene Corp, Madison, NJ USA
[15] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.327
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
327
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study
    Yu, X.
    Shen, L.
    Hao, J.
    Wang, L.
    Pan, H.
    Han, G.
    Xu, J.
    Zhang, Y.
    Yang, S.
    Ying, J.
    Li, M.
    Begic, D.
    Lu, B.
    Xu, R.
    ANNALS OF ONCOLOGY, 2015, 26 : 66 - 67
  • [2] Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).
    Goldstein, David
    Von Hoff, Daniel D.
    Chiorean, E. Gabriela
    Reni, Michele
    Tabernero, Josep
    Ramanathan, Ramesh K.
    Aly, Abdalla
    Botteman, Marc
    Wilkersen, Julia
    Margunato-Debay, Sandra
    Lu, Brian
    Louis, Chrystal Ursula
    Renschler, Markus Frederic
    McGovern, Desmond Micahel Thomas
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Gemcitabine (Gem) and nab-paclitaxel (nab-P) in patients (pts) with refractory advanced pancreatic cancer
    Palacio, Sofia
    Akunyili, Ikechukwu Immanuel
    Ernani, Vinicius
    Macintyre, Jessica
    Merchan, Jaime R.
    Pollack, Terri
    Reis, Isildinha
    Restrepo, Maria H.
    Lima, Caio Max S. Rocha
    Hosein, Peter Joel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [4] A PHASE I/II TRIAL OF WEEKLY NAB-PACLITAXEL (nab-P) plus GEMCITABINE(G) WITH METASTATIC PANCREATIC CANCER(MPC)
    Ikeda, Masafumi
    Ueno, Hideki
    Ueno, Makoto
    Mizuno, Nobumasa
    Ioka, Tatsuya
    Omuro, Yasushi
    Nakajima, Takako
    Furuse, Junji
    ANNALS OF ONCOLOGY, 2014, 25
  • [5] nab-paclitaxel (nab-P) plus nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).
    Firdaus, Irfan
    Waterhouse, David Michael
    Gutierrez, Martin
    Wainberg, Zev A.
    George, Ben
    Kelly, Karen
    Bekaii-Saab, Tanios S.
    Carrizosa, Daniel R.
    Soliman, Hatem Hussein
    Fraser, Cindy Duval
    Ko, Amy
    Pierce, Daniel W.
    Manax, Victoria G.
    Stergiopoulos, Sotirios G.
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [6] Efficacy and safety of nab-Paclitaxel (nab-P) plus gemcitabine (Gem) vs gem alone in patients (Pts) with metastatic pancreatic cancer (MPC) treated to progressive disease (PD) in the phase III MPACT trial
    Vogel, A.
    Penenberg, D.
    McGovern, D.
    Romano, A.
    Michael, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S455 - S455
  • [7] Phase III study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with metastatic pancreatic adenocarcinoma (mPC): Subgroup analysis of Canadian pts from the MPACT trial
    Tehfe, Mustapha Ali
    Dowden, Scot D.
    Kennecke, Hagen F.
    El-Maraghi, Robert Hassan
    Lesperance, Bernard
    Couture, Felix
    Letourneau, Richard
    Penenberg, Darryl Neil
    Romano, Alfredo
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [8] Phase I study of nivolumab (Nivo) plus nab-paclitaxel (nab-P) plus gemcitabine (Gem) in advanced pancreatic cancer (APC).
    Wainberg, Zev A.
    Hochster, Howard S.
    Kim, Edward Jae-Hoon
    George, Ben
    Kalyan, Aparna
    Chiorean, E. Gabriela
    Waterhouse, David Michael
    Gutierrez, Martin
    Parikh, Aparna Raj
    Jain, Rishi
    Carrizosa, Daniel R.
    Soliman, Hatem Hussein
    Bhore, Rafia
    Banerjee, Sibabrata
    Lyons, Larry
    Louis, Chrystal Ursula
    Ong, Teng Jin
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [9] SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study
    Von Hoff, D. D.
    Ramanathan, R.
    Borad, M.
    Laheru, D.
    Smith, L.
    Wood, T.
    Korn, R.
    Desai, N.
    Iglesias, J.
    Hidalgo, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Economic evaluation for the United States (US) of gemcitabine (GEM), nab-paclitaxel plus gemcitabine (NAB-P plus GEM), and FOLFIRINOX as first-line treatment for metastatic pancreatic cancer (MPC)
    Gharaibeh, Mahdi
    McBride, Ali
    Bootman, J. Lyle
    Cranmer, Lee D.
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345